National Eye Institute; Notice of Closed Meeting, 53513 [2017-24760]
Download as PDF
<![CDATA[
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 220 / Thursday, November 16, 2017 / Notices
Serial Number PCT/US2013/050688,
filed 07/16/2013; HHS Reference No. E–
162–2013/0–US–03, United States
Patent Application Serial Number 13/
943,430, filed 07/16/2013; HHS
Reference No. E–162–2013/0–EP–04,
European Patent Application Serial
Number 13819718.1, filed 02/05/2015;
and HHS Reference No. E–162–2013/0–
JP–05, Japanese Patent Application
Serial Number 2015–523183, filed 01/
08/2015. All rights in these inventions
have been assigned to the Government
of the United States of America.
The prospective exclusive patent
commercialization license territory may
be worldwide and the field of use may
be limited to: ‘‘Use of the licensed
patent rights for the development,
manufacture, and sale of a lateral flow
device for detection of antineoplastic
drugs from surfaces’’.
Many types of cancers are treated
with antineoplastic drugs, also known
as anti-cancer drugs or chemotherapy.
Exposure of healthcare workers to these
hazardous drugs from contaminated
surfaces may cause acute and long-term
effects. Approximately eight (8) million
United States healthcare workers are
potentially exposed to these hazardous
drugs. Although there are potential
therapeutic benefits of hazardous drugs
that outweigh the risks of side effects for
ill patients, healthcare workers are
exposed to the risk with the same side
effects with no therapeutic benefit.
Occupational exposures to hazardous
drugs can lead to skin rashes and major
reproductive effects, which include
increased fetal loss, congenital
malformations, low birth weight,
congenital abnormalities, and infertility.
The risk of cancer is also increased after
exposure to these drugs.
This invention, developed within the
National Institute for Occupational
Safety and Health at the Centers for
Disease Control and Prevention,
describes a lateral flow assay-based
antineoplastic drug detection method
that utilizes antibodies specific for
individual drugs. It uses detectors for
the assessment of drug residues on
surfaces, which can be incorporated into
small, portable drug detection devices
that allow healthcare workers to sample
surfaces in near real time, avoiding the
need to take samples back to the
laboratory to be tested.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent
commercialization license will be
royalty bearing and may be granted
unless within fifteen (15) days from the
date of this published notice, the
National Institute of Allergy and
Infectious Diseases receives written
VerDate Sep<11>2014
16:52 Nov 15, 2017
Jkt 244001
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
commercialization license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: November 9, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–24774 Filed 11–15–17; 8:45 am]
BILLING CODE 4140–01–P
53513
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: November 9, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–24760 Filed 11–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–4344–
DR; Docket ID FEMA–2017–0001]
California; Amendment No. 5 to Notice
of a Major Disaster Declaration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
National Institutes of Health
SUMMARY:
AGENCY:
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Eye Institute.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual grant
applications conducted by the
NATIONAL EYE INSTITUTE, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Eye Institute.
Date: December 3–5, 2017.
Time: 6:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 6C6, 31
Center Drive, Bethesda, MD 20892.
Contact Person: Sheldon S. Miller, Ph.D.,
Scientific Director, National Institutes of
Health, National Eye Institute, Bethesda, MD
20892, (301) 451–6763.
Information is also available on the
Institute’s/Center’s home page:
www.nei.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
PO 00000
Frm 00064
Fmt 4703
Sfmt 9990
This notice amends the notice
of a major disaster declaration for the
State of California (FEMA–4344–DR),
dated October 10, 2017, and related
determinations.
This amendment was issued
November 7, 2017.
FOR FURTHER INFORMATION CONTACT:
Dean Webster, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW.,
Washington, DC 20472, (202) 646–2833.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the incident period for
this disaster is closed effective October
31, 2017.
DATES:
The following Catalog of Federal Domestic
Assistance Numbers (CFDA) are to be used
for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora
Brown Fund; 97.032, Crisis Counseling;
97.033, Disaster Legal Services; 97.034,
Disaster Unemployment Assistance (DUA);
97.046, Fire Management Assistance Grant;
97.048, Disaster Housing Assistance to
Individuals and Households In Presidentially
Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance—
Disaster Housing Operations for Individuals
and Households; 97.050 Presidentially
Declared Disaster Assistance to Individuals
and Households—Other Needs; 97.036,
Disaster Grants—Public Assistance
(Presidentially Declared Disasters); 97.039,
Hazard Mitigation Grant.
Brock Long,
Administrator, Federal Emergency
Management Agency.
[FR Doc. 2017–24910 Filed 11–15–17; 8:45 am]
BILLING CODE 9111–23–P
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 82, Number 220 (Thursday, November 16, 2017)]
[Notices]
[Page 53513]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24760]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Board of Scientific
Counselors, National Eye Institute.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual grant applications conducted by the NATIONAL EYE INSTITUTE,
including consideration of personnel qualifications and performance,
and the competence of individual investigators, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, National Eye
Institute.
Date: December 3-5, 2017.
Time: 6:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, Conference
Room 6C6, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Sheldon S. Miller, Ph.D., Scientific Director,
National Institutes of Health, National Eye Institute, Bethesda, MD
20892, (301) 451-6763.
Information is also available on the Institute's/Center's home
page: www.nei.nih.gov, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.867,
Vision Research, National Institutes of Health, HHS)
Dated: November 9, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-24760 Filed 11-15-17; 8:45 am]
BILLING CODE 4140-01-P
